Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

PD biomarkers—use of α-synuclein reaches new levels

Nature Reviews Neurology volume 7, pages 308–309 (2011)Cite this article

Subjects

Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mollenhauer, B. et al. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230–240 (2011).

    Article  CAS  Google Scholar 

  2. Montine, T. J. et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682–2685 (2010).

    Article  Google Scholar 

  3. Sonnen, J. A., Montine, K. S., Quinn, J. F., Breitner, J. C. & Montine, T. J. Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J. Alzheimers Dis. 19, 301–309 (2010).

    Article  Google Scholar 

  4. Trojanowski, J. Q. et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6, 230–238 (2010).

    Article  CAS  Google Scholar 

  5. Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59, 512–519 (2006).

    Article  CAS  Google Scholar 

  6. Shi, M. et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570–580 (2011).

    Article  CAS  Google Scholar 

  7. Mata, I. F. et al. SNCA variant associated with Parkinson disease and plasma α-synuclein level. Arch. Neurol. 67, 1350–1356 (2010).

    Article  Google Scholar 

  8. Devic, I. et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain doi:10.1093/brain/awr015.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Washington, 300 9th Avenue, Seattle, 98104, WA, USA

    Thomas J. Montine

Authors
  1. Thomas J. Montine
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montine, T. PD biomarkers—use of α-synuclein reaches new levels. Nat Rev Neurol 7, 308–309 (2011). https://doi.org/10.1038/nrneurol.2011.66

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.66

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing